MYUNGMOON Pharm Co., Ltd. Statistics
Want to see KR:017180 full AI Analyst Report?
MYUNGMOON Pharm Co., Ltd. (017180) Stock Statistics & Valuation Metrics
Total Valuation
MYUNGMOON Pharm Co., Ltd. has a market cap or net worth of KRW 34.00B. The enterprise value is KRW 128.25B.
- Market Cap
- KRW 34.00B
- Enterprise Value
- KRW 128.25B
Share Statistics
MYUNGMOON Pharm Co., Ltd. has 33,953,453 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 33,953,453
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
MYUNGMOON Pharm Co., Ltd.’s return on equity (ROE) is 0.02 and return on invested capital (ROIC) is 1.58%.
- Return on Equity (ROE)
- 0.02
- Return on Assets (ROA)
- 0.01
- Return on Invested Capital (ROIC)
- 1.58%
- Return on Capital Employed (ROCE)
- 0.04
- Revenue Per Employee
- 631.87M
- Profits Per Employee
- 6.13M
- Employee Count
- 309
- Asset Turnover
- 0.72
- Inventory Turnover
- 2.27
Valuation Ratios
The current PE Ratio of MYUNGMOON Pharm Co., Ltd. is -2.68. MYUNGMOON Pharm Co., Ltd.’s PEG ratio is -0.01.
- PE Ratio
- -2.68
- PS Ratio
- 0.17
- PB Ratio
- 0.40
- Price to FCF
- -1.30
- Price to Operating Cash Flow
- -2.10
- PEG Ratio
- -0.01
Income Statement
In the last 12 months, MYUNGMOON Pharm Co., Ltd. had revenue of 195.25B and earned 1.90B in profits. Earnings per share was 56.70.
- Revenue
- 195.25B
- Gross Profit
- 107.19B
- Operating Income
- 6.83B
- Pretax Income
- 2.65B
- Net Income
- 1.90B
- EBITDA
- 10.13B
- Earnings Per Share (EPS)
- 56.70
Cash Flow
In the last 12 months, operating cash flow was -16.48B and capital expenditures -10.06B, giving a free cash flow of -26.54B billion.
- Operating Cash Flow
- -16.48B
- Free Cash Flow
- -26.54B
- Free Cash Flow per Share
- -781.57
Dividends & Yields
MYUNGMOON Pharm Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -76.85%
- Earnings Yield
- -36.36%
Stock Price Statistics
- Beta
- 0.03
- 52-Week Price Change
- -42.08%
- 50-Day Moving Average
- 1223.20
- 200-Day Moving Average
- 1450.36
- Relative Strength Index (RSI)
- 22.25
- Average Volume (3m)
- 183.27K
Important Dates
MYUNGMOON Pharm Co., Ltd. upcoming earnings date is Mar 24, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 13, 2026
- Next Earnings Date
- Mar 24, 2027
- Ex-Dividend Date
- ―
Financial Position
MYUNGMOON Pharm Co., Ltd. as a current ratio of 0.96, with Debt / Equity ratio of 99.89%
- Current Ratio
- 0.96
- Quick Ratio
- 0.55
- Debt to Market Cap
- 1.56
- Net Debt to EBITDA
- 9.16
- Interest Coverage Ratio
- 1.34
Taxes
In the past 12 months, MYUNGMOON Pharm Co., Ltd. has paid 1.23B in taxes.
- Income Tax
- 1.23B
- Effective Tax Rate
- 0.46
Enterprise Valuation
MYUNGMOON Pharm Co., Ltd. EV to EBITDA ratio is -31.36, with an EV/FCF ratio of -4.39.
- EV to Sales
- 0.59
- EV to EBITDA
- -31.36
- EV to Free Cash Flow
- -4.39
- EV to Operating Cash Flow
- -7.07
Balance Sheet
MYUNGMOON Pharm Co., Ltd. has KRW 6.05B in cash and marketable securities with KRW 87.54B in debt, giving a net cash position of -KRW 81.49B billion.
- Cash & Marketable Securities
- KRW 6.05B
- Total Debt
- KRW 87.54B
- Net Cash
- -KRW 81.49B
- Net Cash Per Share
- -KRW 2,399.99
- Tangible Book Value Per Share
- KRW 2,668.30
Margins
Gross margin is 58.69%, with operating margin of -3.64%, and net profit margin of -6.32%.
- Gross Margin
- 58.69%
- Operating Margin
- -3.64%
- Pretax Margin
- -6.17%
- Net Profit Margin
- -6.32%
- EBITDA Margin
- -1.87%
- EBIT Margin
- -3.64%
Analyst Forecast
The average price target for MYUNGMOON Pharm Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 2.66%
- EPS Growth Forecast
- -947.63%
Scores
- Smart Score
- ―
- AI Score
- 43

